| Literature DB >> 25731571 |
Yuka Asano1, Shinichiro Kashiwagi, Masatsune Shibutani, Sadaaki Yamazoe, Satoru Noda, Katsunobu Sakurai, Hisashi Nagahara, Kenjiro Kimura, Hidemi Kawajiri, Takahiro Toyokawa, Ryosuke Amano, Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Hiroshi Ohtani, Tsutomu Takashima, Masakazu Yashiro, Naoyoshi Onoda, Kiyoshi Maeda, Masaichi Ohira, Kosei Hirakawa.
Abstract
There are only a few reports in the literature about the effect of recombinant human soluble thrombomodulin (rTM) in patients with solid carcinoma with disseminated intravascular coagulation (DIC). A retrospective study of 40 patients with solid carcinoma with DIC was performed between February 2009 and April 2013. The withdrawal rate was 32.5% (13/40 patients), and the 28-day survival rate was 40.0% (16/40 patients). Patients with successful withdrawal of DIC had significantly better outcomes (p<.001). Therapy with rTM is one of the treatment options for patients with solid carcinoma with DIC.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25731571
Source DB: PubMed Journal: Gan To Kagaku Ryoho ISSN： 0385-0684